863180-05-6

Basic information

• Product Name: A2-PE
• Synonyms: 2-[(1E,3E,5E,7E)-2,6-DiMethyl-8-(2,6,6-triMethyl-1-cyclohexen-1-yl)-1,3,5,7-octatetraen-1-yl]-1-[4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-4-[(1E,3E,5E)-4-Methyl-6-(2,6,6-triMethyl-1-cyclohexen-1-yl)-1,3,5;A2-PE
• CAS NO: 863180-05-6
• Molecular Formula: C77H125NO8P+
• Molecular Weight: 1223.792061
• Product Categories: Pharmaceuticals;Retinoids;Intermediates & Fine Chemicals
• Mol File: 863180-05-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: A2-PE(CAS DataBase Reference)
• NIST Chemistry Reference: A2-PE(863180-05-6)
• EPA Substance Registry System: A2-PE(863180-05-6)

Safety Data

• Hazardous Substances Data: 863180-05-6(Hazardous Substances Data)

Usage

Description

A2-PE, also known as A2-E, is a fluorescent bisretinoid pigment that forms as a byproduct of the visual cycle in vertebrates. It accumulates in retinal pigment epithelial (RPE) cells over time, leading to a decline in cellular function and contributing to age-related macular degeneration (AMD).

Uses

Used in Pharmaceutical Industry:
A2-E is used as a target for drug development to treat age-related macular degeneration (AMD). By inhibiting the formation or promoting the clearance of A2-E, potential therapeutic agents can help slow down or prevent the progression of AMD.
Used in Research:
A2-E is used as a model compound in research studies to investigate the mechanisms of AMD and the effects of various interventions on RPE cells and the retina. This helps in understanding the pathophysiology of the disease and identifying potential therapeutic targets.
Used in Diagnostics:
A2-E can be used as a biomarker for the early detection and monitoring of age-related macular degeneration. The presence and accumulation of A2-E in the retina can be assessed using imaging techniques, such as autofluorescence imaging, to identify individuals at risk for developing AMD.
Used in Drug Delivery Systems:
A2-E can be used as a target for drug delivery systems to improve the treatment of age-related macular degeneration. Novel drug delivery systems, such as nanoparticles or liposomes, can be designed to specifically target and clear A2-E from RPE cells, enhancing the therapeutic efficacy and reducing side effects.